Related Experiment Video

Updated: Nov 25, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

575

Fedratinib hydrochloride to treat intermediate-2 or high-risk primary or secondary myelofibrosis

M Schiffer1, A Kowalski1, J Zhao1

  • 1Department of Pharmacy, Yale New Haven Hospital, New Haven, Connecticut, USA.

Drugs of Today (Barcelona, Spain : 1998)
|December 17, 2020
PubMed

Insights

Fedratinib is an FDA-approved JAK2 inhibitor for myelofibrosis, effectively reducing spleen size and symptoms. Initial safety concerns regarding Wernicke

Area of Science:

  • Pharmacology and Oncology
  • Hematology

Background:

  • Fedratinib hydrochloride is a selective Janus kinase 2 (JAK2) inhibitor.
  • It is approved for intermediate-2 or high-risk primary or secondary myelofibrosis.
  • Myelofibrosis is a serious myeloproliferative neoplasm.

Purpose of the Study:

  • To review the pharmacology, safety, and efficacy of fedratinib.
  • To discuss the future directions for fedratinib in treating myeloproliferative neoplasms.

Main Methods:

  • Review of data from Phase II and III JAKARTA-2 and JAKARTA trials.
  • Analysis of adverse effects and safety concerns, including Wernicke's encephalopathy.

Main Results:

  • Significant reduction in splenomegaly and myelofibrosis symptom burden.
  • Common adverse effects include anemia, gastrointestinal issues, and elevated liver enzymes.
  • Initial concerns regarding Wernicke's encephalopathy were not substantiated by further investigation.

Conclusions:

  • Fedratinib is an effective treatment for myelofibrosis with a manageable safety profile.
  • Further investigation confirmed no clear link between fedratinib and Wernicke's encephalopathy.
  • The drug's use in myeloproliferative neoplasms warrants continued exploration.
Keywords:
AnemiaDisorders of white blood cellsFedratinib hydrochlorideHematologic diseasesJanus kinase 2 (JAK2) inhibitorsMyelofibrosisMyeloproliferative diseases

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

455

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
319
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
290
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
96
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
4.3K